Having observed a role of CXCR4 activation in gemcitabine resistance and potentiation of survival pathways, we investigated if the small-molecule CXCR4 antagonist, AMD3100, could diminish CXCL12-induced chemoresistance in pancreatic cancer cells. This evidence concerns the gene CXCL12 and pancreatic neoplasm.